Proceedings of the Fifty-Second Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N

Total Page:16

File Type:pdf, Size:1020Kb

Proceedings of the Fifty-Second Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N PROCEEDINGS OF THE FIFTY-SECOND ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1960 Robert W. Berliner J Clin Invest. 1960;39(6):966-1042. https://doi.org/10.1172/JCI104118. Research Article Find the latest version: https://jci.me/104118/pdf PROCEEDINGS OF THE FIFTY-SECOND ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1960 PRESIDENTIAL ADDRESS PROBLEMS OF THE SOCIETY, 1960 By ROBERT W. BERLINER It is one of the ancient and, to the victim, barbaric in some subspecialties, Sunday evening. In order to make customs of this rite of spring for the president to ad- this possible, the Federation gave up its Sunday afternoon dress the members of the Society on some aspect of the general meeting. It was also agreed that following a current scene in clinical investigation. The message is reasonable trial of this arrangement there would be a then recorded in the Journal of the Society where it is review to determine whether changes were indicated. available for posterity, or rather for later presidents in A possible expansion of the section meetings was to be search of suitable quotations pertinent to their own ad- subject to such a review. It was conceded, without com- dresses. I had thought that the subjects I plan to dis- mitment, that the Society might entertain the possibility cuss were of only immediate interest and too topical to that such expansion would replace part of its Monday have any significance beyond the next year or so. How- general scientific session. The time for such a review ever, a reading of the recently compiled history of the is at hand and I feel it appropriate to indicate to the Society indicates that these same subj ects have been members of the Society the possible factors upon which the center of discussion almost since the Society was or- our decision should be based. ganized. These two matters-the form of the meeting I believe it safe to say that the section meetings have and the criteria for the election of new members-again been highly successful. They have permitted the presen- demand the attention of the membership. The considera- tation of a considerable number of papers which, because tions that influence our attitudes on these questions to- of the limitations of time, could not have been included day may differ from those which have been debated in in the general programs of the two societies. More im- the past and from those which will determine the posi- portant, they have permitted the inclusion of a number tion of the Society in the future. Nevertheless, we must of excellent papers which, because they deal with tech- make decisions based on the current situation, recog- nical matters of a higlhly specialized nature, would be nizing that they will require continuous reconsideration inappropriate for a general audience, but are received and possible revision in the future. with interest and insight by workers in the same field. Since action on each of these matters is, at this time, Discussion is far less inhibited by the smaller audience required of the Council and the membership, it seems ap- and the much less overwhelming size of the meeting propriate that the presidential address be devoted to an halls and is encouraged by the greater community of attempt to clarify the issues involved. The time avail- interest and understanding. able for the transaction of business at our annual meet- As to the increase in the number of papers presented, ing is sufficiently limited to preclude much adherence to those submitted to the Society have fared somewhat the forms of democratic procedure. Nevertheless, the better both absolutely and relatively than those sub- officers of the Society act in the conviction that they mitted to the Federation. The section meetings have understand and represent the will of the majority of the permitted the presentation of more than twice as many members and, although the formal opportunities for the of the papers submitted to the Society: just under one members to make known their wishes are few, the in- of every three papers offered finds a place on one or an- formal occasions are many. It is in this spirit that I other program. Because of the sacrifice of part of its place before the Society my personal convictions on the general session, there is a smaller increase in the num- problems requiring decision. ber of papers accepted for the Federation program. In As you may know, three years ago the president ap- addition, because of a continuing rapid increase in the pointed a committee of the Council to meet with repre- number of abstracts submitted to the Federation, only sentatives of the Federation for Clinical Research to ar- one in every six or seven is actually presented. range for the conduct of section meetings on various It is always difficult to evaluate, from an abstract, the subspecialties of clinical investigation. The committee work which it represents, but it is my feeling and the was instructed to plan the meetings, in cooperation with considered opinion of the chairmen of the various sec- the Federation if possible but separately if necessary, and tion meetings, both this year and last, that, except for to arrange that the section meetings should not conflict two of the sections, the programs could not be appreciably with the general scientific program of the Society on expanded without reducing their present high level. Monday. Agreement was reached, and jointly spon- Since three of the sections now meet only in the after- sored meetings were set up for Sunday afternoon and, noon, additional programs could be fitted into the even- 966 AMERICAN SOCIETY FOR CLINICAL INVESTIGATION 967 ings by further subdivision of the more prolific special believe that it would adequately meet this problem. areas, but it must be conceded that the evening sessions It is true that there would be a sharp decrease in the are considerably less satisfactory than those in the candidates for election next year if all those over 40 afternoon. were dropped from consideration and their elimination This, then, is the background upon which a decision from consideration were on such an arbitrary basis that concerning the future of the section programs must be it could not be considered a reflection on them personally. based. I, personally, am opposed to their expansion. Of the 193 candidates for election this year, 86 would There is today, as there was when Dr. Meltzer delivered not be eligible for consideration next year solely on the the first presidential address to the Society, cause for basis of age. An additional 34 candidates from the concern about the science of clinical medicine. The group nominated in 1958 would either have been elected basis for this concern is, however, entirely different. The or dropped from consideration, bringing the total num- establishment of the science of clinical medicine as a ber carried over from this year to something under 73 branch distinct from its practice has long since been ac- and most likely around 50. If we could then anticipate complished. Today we find clinical investigation grown next year a number of new proposals not greater than the so massive that it has become subdivided into many average of recent years, the list to be considered would smaller branches, each of which has tended to fuse back be at its lowest level in the last ten years. However, I with the corresponding basic science, thus leading not doubt that this sitaution could last very long. An ex- only to a widening separation between the science and traordinarily large number of candidates was proposed practice of medicine, but also to an increasing indi- in 1958-so many, in fact, that even after reduction of vidualization of the specialized investigative areas. The the list by two previous elections there were still more growing complexity of technology as well as the snow- candidates up for election this year from those nominated balling accretion of information in each field makes it in 1958 than the totals proposed in either 1959 or 1960. virtually impossible for an individual to be expert in Furthermore, of the candidates proposed this year the more than one. Nevertheless, few of us can afford ig- unusually large number of 26, or 39 per cent, would not norance in fields outside our own, and a single day's be eligible next year under the proposed amendment, 18 exposure to a reasonable sampling of the better work in of these 26 being already past the age of 40. Thus the clinical investigation is all too inadequate. number who would be dropped this year is unusually large That only a minority of papers submitted finds a place in several respects. It seems clear that the membership, on the program is, perhaps, unfortunate, but so long as anticipating possible adoption of the amendment, has this fact does not discourage submission of excellent ma- proposed the names of a large number of candidates for terial for the program it should not be an important con- whom it might be the last chance. It seems virtually cer- sideration. There is, these days, no lack of opportunity tain, however, that in the future, in view of the limited for communication. The ease and speed of travel and period of eligibility, candidates will be proposed in equal the availability of funds to support it has led to such numbers but at an earlier age, when it may be even more a massive proliferation of meetings, conferences and difficult to evaluate their independent contributions.
Recommended publications
  • Diuretic Cocktail"
    Clinical evaluation of a "diuretic cocktail" LAWRENCE J. GALLA, A.B., D.O., and WIL- acetazoleamide depressing hydration of carbon LIAM BALDWIN, JR., D.O., F.A.C.0.1., York, dioxide, exchange resins drawing salt from food Pennsylvania in the intestinal tract, or water diuresis. Therefore, diuretic therapy should be planned to permit daily salt and water balance. The treatment should take into account the particular type of fluid or electro- The characteristics of an ideal diuretic can be lyte to be removed, the need for speed in its re- easily enumerated; it should be effective without moval, and the setting in which it will be done. producing electrolyte disturbance, nephrotoxicity, Oral diuretics, for example, are desirable; however, sensitivity, refractoriness, or cardiac toxicity. How- they are often not powerful enough for acute or ever, in practice, a compound encompassing these emergency problems, or they may irritate the pa- properties remains to be found. Furthermore, be- tient's stomach. It may be said that oral diuretics cause of the many factors involved in the patho- are useful in cases where a modest diuretic action logic states that result in abnormal water retention, is satisfactory. Other clinical situations are met by a universal diuretic—that is, one that will work in other means. every situation—has yet to to be made available. Diet is rather important. Patients with edema In recent years a number of new diuretic drugs will probably have to accept a low-salt diet sooner utilizing various physiologic principles have ap- or later; the sooner they start, the sooner better peared.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Therapeutic Combination and Use of Dll4 Antagonist Antibodies and Anti-Hypertensive Agents
    (19) TZZ Z_T (11) EP 2 488 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/395 (2006.01) A61P 35/00 (2006.01) 06.04.2016 Bulletin 2016/14 A61P 9/12 (2006.01) (21) Application number: 10824244.7 (86) International application number: PCT/US2010/053064 (22) Date of filing: 18.10.2010 (87) International publication number: WO 2011/047383 (21.04.2011 Gazette 2011/16) (54) THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS THERAPEUTISCHE KOMBINATION UND VERWENDUNGG MIT DLL4-ANTAGONISTISCHE ANTIKÖRPER UND MITTEL GEGEN BLUTHOCHDRUCK COMBINAISON THÉRAPEUTIQUE ET UTILISATION D’ANTICORPS ANTAGONISTES DE D LL4 ET D’AGENTS ANTI-HYPERTENSEURS (84) Designated Contracting States: US-A1- 2009 221 549 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • SMITH D C ET AL: "222 A first-in-human, phase I PL PT RO RS SE SI SK SM TR trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with (30) Priority: 16.10.2009 US 252473 P advanced solid tumors", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, (43) Date of publication of application: OXFORD, GB, vol. 8, no. 7, 1 November 2010 22.08.2012 Bulletin 2012/34 (2010-11-01), page 73, XP027497910, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71927-3 (60) Divisional application: [retrieved on 2010-11-01] & Smith et al: "A 16155324.3 first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem (73) Proprietor: Oncomed Pharmaceuticals, Inc.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • ARCI Uniform Classification Guidelines for Foreign Substances, Or Similar State Regulatory Guidelines, Shall Be Assigned Points As Follows
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Effect of Mersalyl on the Thick Ascending Limb of Henle's Loop
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 4 (1973). p. 245—251 Effect of mersalyl on the thick ascending limb of Henle's loop MAURICE BURG and NORDICA GREEN Laboratory of Kidney and Electrolyte Metabolism, National Heart andLung Institute, National Institutes of Health, Bethesda, Maryland Effect of mersalyl on the thick ascending limb of Henle's loop. de Henle isolée et perfusee peut être identifié a son effet diuretique The cortical portion of the thick ascending limb of Henle's loop in vivo. Le mersalyl dans Ic bain est inefficace, excepté a une was dissected from rabbit kidneys and perfused in vitro. There concentration plus élevée (10—i M)etalors I'effet n'est pas was active chloride transport resulting in net sodium chloride reversible. Nous concluons que l'effet diurétique des mercuriels reabsorption from the tubule lumen, with the electrical potential est lie, au moms en partie, a l'action inhibitrice de ces drogues difference (PD) oriented positive in the lumen. The addition of sur le transport actif de chlore dans Ia partie large de Ia branche mersalyl ( iO M)tothe lumen caused the PD and net Cl flux ascendante de l'anse de Henle. to decrease, indicating inhibition of the active Cl transport. The decrease in PD caused by the drug in the lumen was approxi- mately 50% at concentrations equal to or greater than iO M, Mercurial diuretics were extensively used and studied andthe decrease in CI transport (measured at 3 x l0 M)was until they were supplanted in the past few years by more similar in magnitude.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • Studies on Structure Diuretic Activity Relationships of Organic Compounds of Mercury
    STUDIES ON STRUCTURE DIURETIC ACTIVITY RELATIONSHIPS OF ORGANIC COMPOUNDS OF MERCURY R. H. Kessler, … , R. Lozano, R. F. Pitts J Clin Invest. 1957;36(5):656-668. https://doi.org/10.1172/JCI103466. Research Article Find the latest version: https://jci.me/103466/pdf STUDIES ON STRUCTURE DIURETIC ACTIVITY RELATIONSHIPS OF ORGANIC COMPOUNDS OF MERCURY' By R. H. KESSLER,2 R. LOZANO,3 AND R. F. PITTS (From Thc Department of Physiology, Cornell University Mledical Collcgc, Neczw York, N. Y.) (Submitted for publication December 3, 1956; accepted January 10, 1957) The mercurial diuretics in commiiiion use today are available or easily prepared as starting ma- exhibit certain basic similarities in structure. All terials. Mercuration in methyl alcohol is relatively are mercurated derivatives of substituted three easy and yields of the 3-mercuri-2-methoxy propyl carbon compounds of the type indicated below, in end products are satisfactory. Logical questions which the three substituents are designated X, OY, which arise include: Is the three carbon side chain and R. of the presently used diuretics an essential or opti- H H H mal element of diuretic structure, or is it merely a matter of preparative convenience? X-Hg-C-C-C(-R The diuretic activity of organic mercurial com- of HOY H pounds has recently been ascribed to inhibition sulfhydryl enzymes concerned with the renal tu- According to Friedman ( 1 ), the nature of the X blular reabsorption of sodium and chloride ions substituent (usually halogen, theophylline or thio- (2, 3). Mercuric chloride and certain relatively glycolate) has no effect on diuretic potency if the simple organo-mercurials, including bromomer- compound is given intravenously, but does influ- curi-methane, bromo-mercuri-benzene and para- ence both hyperacute (cardiac and respiratory chloromercuri-benzoate, are potent and more or arrest) and acute (7 to 14-day) renal toxicity.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]